Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.32 |
| ▸ | ACP3 | P15309 | 7/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | MMP8 | P22894 | 2/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | FDPS | P14324 | 2/20 | 0.33 |
| ▸ | MMP14 | P50281 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2264057 | 0.91 | ACP3 (0.41) | ACP3SRCMMP8CA12MMP14 | |
| Hydrochloric Acid SCHEMBL2892897 | 0.89 | ACP3 (0.39) | ACP3KDM4EALDH1A1LMNAHTT | |
| Hydrochloric Acid SCHEMBL2264240 | 0.87 | ACP3 (0.37) | ACP3KDM4ESRCRAB9AMMP8 | |
| Hydrochloric Acid SCHEMBL2259347 | 0.85 | MMP2 (0.43) | ACP3SRCMMP8CA12CA1 | |
| Hydrochloric Acid SCHEMBL2260405 | 0.84 | MMP2 (0.39) | ACP3SRCRAB9AMMP8CA12 | |
| SCHEMBL4334656 | 0.84 | MMP2 (0.44) | ACP3SRCMMP8CA12CA1 | |
| Hydrochloric Acid SCHEMBL2259031 | 0.82 | ACP3 (0.39) | ACP3KDM4EALDH1A1LMNAHTT | |
| Hydrochloric Acid SCHEMBL2899630 | 0.82 | ACP3 (0.43) | ACP3KDM4EALDH1A1LMNAHTT | |
| Hydrochloric Acid SCHEMBL3928802 | 0.80 | ACP3 (0.41) | ACP3KDM4EALDH1A1LMNAHTT | |
| Hydrochloric Acid SCHEMBL2263262 | 0.80 | MMP8 (0.36) | KDM4EALDH1A1LMNAHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090259042-A1 | ELECTROCHROMIC COMPOUNDS | NTERA LIMITED (IE) | 2009-10-15 | — | — | US | claimed |
| US-20060110638-A1 | Electrochromic compounds | NTERA LIMITED (IE) | 2006-05-25 | — | — | US | claimed |
| EP-1594938-A1 | ELECTROCHROMIC COMPOUNDS | Ntera Limited (IE) | 2005-11-16 | — | — | EP | claimed |
| WO-2004067673-A1 | ELECTROCHROMIC COMPOUNDS | NTERA LIMITED (IE) | 2004-08-12 | — | — | WO | claimed |
| EP-1443091-A1 | Electrochromic compounds | Ntera Limited (IE) | 2004-08-04 | — | — | EP | claimed |
| US-8999430-B2 | Method of manufacturing display element | KONICA MINOLTA HOLDINGS, INC. (JP) | 2015-04-07 | — | — | US | disclosed |
| EP-2149816-B1 | METHOD OF MANUFACTURING AN ELECTROCHROMIC DISPLAY ELEMENT | KONICA MINOLTA HOLDINGS INC (JP) | 2014-05-07 | — | — | EP | disclosed |
| US-8014056-B2 | Display element and method of driving the same | KONICA MINOLTA HOLDINGS, INC. (JP) | 2011-09-06 | — | — | US | disclosed |
| US-8004742-B2 | Electrochromic display device | KONICA MINOLTA HOLDINGS, INC. (JP) | 2011-08-23 | — | — | US | disclosed |
| US-20100166946-A1 | METHOD OF MANUFACTURING DISPLAY ELEMENT | KONICA MINOLTA HOLDINGS, INC. (JP) | 2010-07-01 | — | — | US | disclosed |
| US-20100091353-A1 | DISPLAY ELEMENT AND METHOD OF DRIVING THE SAME | KONICA MINOLTA HOLDINGS, INC. (JP) | 2010-04-15 | — | — | US | disclosed |
| EP-2149816-A1 | METHOD FOR PRODUCTION OF DISPLAY ELEMENT | Konica Minolta Holdings, Inc. (JP) | 2010-02-03 | — | — | EP | disclosed |
| US-20090259042-A1 | ELECTROCHROMIC COMPOUNDS | NTERA LIMITED (IE) | 2009-10-15 | — | — | US | disclosed |
| EP-2096490-A1 | DISPLAY ELEMENT AND METHOD OF DRIVING THE SAME | Konica Minolta Holdings, Inc. (JP) | 2009-09-02 | — | — | EP | disclosed |
| US-7567371-B2 | Electrochromic compounds | NTERA LIMITED (IE) | 2009-07-28 | — | — | US | disclosed |
| EP-2040115-A1 | ELECTROCHROMIC DISPLAY DEVICE | Konica Minolta Holdings, Inc. (JP) | 2009-03-25 | — | — | EP | disclosed |
| US-20060110638-A1 | Electrochromic compounds | NTERA LIMITED (IE) | 2006-05-25 | — | — | US | disclosed |
| EP-1594938-A1 | ELECTROCHROMIC COMPOUNDS | Ntera Limited (IE) | 2005-11-16 | — | — | EP | disclosed |
| WO-2004067673-A1 | ELECTROCHROMIC COMPOUNDS | NTERA LIMITED (IE) | 2004-08-12 | — | — | WO | disclosed |
| EP-1443091-A1 | Electrochromic compounds | Ntera Limited (IE) | 2004-08-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090259042-A1 | ELECTROCHROMIC COMPOUNDS | ETV6, HCN2, EED | ACHE 161/4885ACP3 2868/4885KDM4E 1692/4885 |
| US-20060110638-A1 | Electrochromic compounds | ETV6, HCN2, EED | ACHE 161/4885ACP3 2868/4885KDM4E 1692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.